Today: 10 June 2026
Browse Category

NASDAQ:QTTB 1 December 2025

Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

Q32 Bio shares jumped as much as 170% intraday on December 1 after announcing the sale of its Phase 2 drug ADX-097 to Akebia Therapeutics for $12 million upfront and up to $592 million in milestones. Trading volume soared into the hundreds of millions. The company will now focus on its lead autoimmune drug, bempikibart, for alopecia areata.
1 December 2025
···

Stock Market Today

  • VS Media Shares Surge Over 300% Premarket on S T Meng Debt-to-Equity Swap
    June 10, 2026, 9:59 AM EDT. VS Media Holdings Limited's shares soared 316.57% to $3.43 in premarket Nasdaq trading on June 10, 2026, following a $3.8 million debt-to-equity conversion agreement with Singapore-linked S T Meng Pte. Ltd. This deal raised VS Media's voting stake in S T Meng to 41.52% from 19%. Despite the dramatic share price rise, VS Media remains a micro-cap firm with a market cap of about $2.29 million and posted a net loss in 2025, raising concerns about its sustainability. The stock's premarket surge reflects investor interest in the company's expanding exposure, but VS Media has yet to generate revenue from its new AI Smart Living initiatives.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
Go toTop